John Hunter Peel Alexander, MD

Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail 200 Morris Street, Durham, NC 27701
Phone (919) 668-8955
Email address john.h.alexander@duke.edu

John H. Alexander, MD, MHS is a cardiologist and Professor of Medicine in the Department of Medicine, Division of Cardiology at Duke University School of Medicine, as well as the Vice Chief, Clinical Research in the Division of Cardiology. He is the Director of Cardiovascular Research at the Duke Clinical Research Institute where he oversees a large group of clinical research faculty and a broad portfolio of cardiovascular clinical trials and observational clinical research programs. He is a member of the American Society of Clinical Investigation.

Dr. Alexander’s clinical interests are in acute and general cardiovascular disease, valvular heart disease, and echocardiology. His research is focused on the translation of novel therapeutic concepts into clinical data through clinical trials, specifically on the therapeutics of acute coronary syndromes, chronic coronary artery disease, and cardiac surgery and on novel methodological approaches to clinical trials. He was on the Executive Committee of the ARISTOTLE trial of apixaban in patients with atrial fibrillation and was the Principal Investigator of the APPRAISE-2 trial of apixaban in patients with acute coronary syndromes.

Dr. Alexander has published extensively and has served as the principal investigator of numerous multicenter clinical trials. He currently serves as the co-chair of the Clinical Trial Transformation Initiative (CTTI).

Education and Training

  • Fellow in Cardiology, Medicine, Duke University, 1996 - 2000
  • Medical Resident, Medicine, Children's Hospital Boston, 1993 - 1996
  • M.D., University of Pennsylvania, 1993

Publications

Berglund, Erik, Lars Wallentin, Jonas Oldgren, Henrik Renlund, John H. Alexander, Christopher B. Granger, Stefan H. Hohnloser, et al. “Effects of apixaban compared with warfarin as gain in event-free time - a novel assessment of the results of the ARISTOTLE trial.” Eur J Prev Cardiol 27, no. 12 (August 2020): 1311–19. https://doi.org/10.1177/2047487319886959.

PMID
31698965
Full Text

Røsjø, H., Z. Hijazi, T. Omland, J. Westerbergh, M. N. Lyngbakken, J. H. Alexander, B. J. Gersh, et al. “Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial.” J Intern Med 288, no. 2 (August 2020): 248–59. https://doi.org/10.1111/joim.13072.

PMID
32350915
Full Text

Perkovic, Vlado, Robert Toto, Mark E. Cooper, Johannes F. E. Mann, Julio Rosenstock, Darren K. McGuire, Steven E. Kahn, et al. “Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial.” Diabetes Care 43, no. 8 (August 2020): 1803–12. https://doi.org/10.2337/dc20-0279.

PMID
32444457
Full Text

Aulin, Julia, Ziad Hijazi, Agneta Siegbahn, Ulrika Andersson, John H. Alexander, Stuart J. Connolly, Michael D. Ezekowitz, et al. “Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials.” J Thromb Haemost, June 8, 2020. https://doi.org/10.1111/jth.14947.

PMID
32510737
Full Text

Diepen, Sean van, Rajendra H. Mehta, Jeffrey D. Leimberger, Shaun G. Goodman, Stephen Fremes, Rachael Jankowich, Matthias Heringlake, et al. “Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery.” J Thorac Cardiovasc Surg 159, no. 6 (June 2020): 2302-2309.e6. https://doi.org/10.1016/j.jtcvs.2019.06.020.

PMID
31358329
Full Text

Diepen, Sean van, Judith S. Hochman, Amanda Stebbins, Carlos L. Alviar, John H. Alexander, and Renato D. Lopes. “Association Between Delays in Mechanical Ventilation Initiation and Mortality in Patients With Refractory Cardiogenic Shock.” Jama Cardiol, May 20, 2020. https://doi.org/10.1001/jamacardio.2020.1274.

PMID
32432650
Full Text

Alexander, John H., Daniel Wojdyla, Amit N. Vora, Laine Thomas, Christopher B. Granger, Shaun G. Goodman, Ronald Aronson, Stephan Windecker, Roxana Mehran, and Renato D. Lopes. “Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.” Circulation 141, no. 20 (May 19, 2020): 1618–27. https://doi.org/10.1161/CIRCULATIONAHA.120.046534.

PMID
32223444
Full Text

Lopes, Renato D., Ariane Vieira Scarlatelli Macedo, Pedro Gabriel Melo de Barros E Silva, Renata Junqueira Moll-Bernardes, Andre Feldman, Guilherme D’Andréa Saba Arruda, Andrea Silvestre de Souza, et al. “Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).” Am Heart J, May 13, 2020. https://doi.org/10.1016/j.ahj.2020.05.002.

PMID
32405071
Full Text

Lopes, Renato D., Ariane Vieira Scarlatelli Macedo, Pedro Gabriel Melo de Barros E Silva, Renata Junqueira Moll-Bernardes, Andre Feldman, Guilherme D’Andréa Saba Arruda, Andrea Silvestre de Souza, et al. “Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.” Am Heart J 226 (May 13, 2020): 49–59. https://doi.org/10.1016/j.ahj.2020.05.002.

PMID
32502882
Full Text

Pages